SCHEMBL3784536

SCHEMBL3784536

Cc1nc2c(Cl)ccc(CC(=O)O)c2c(C)c1Oc1ccc(Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.39
THRA P10827 2/20 0.38
THRB P10828 2/20 0.38
PTGDR2 Q9Y5Y4 6/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPT P10636 1/20 0.36
ENPP3 O14638 1/20 0.36
ALPL P05186 1/20 0.36
ENPP1 P22413 1/20 0.36
XIAP P98170 1/20 0.36
PPARG P37231 2/20 0.36
LMNA P02545 2/20 0.36
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
POLB P06746 1/20 0.35
CHRM1 P11229 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3778902 0.82 PPARD (0.46) EGLN1PTGDR2KDM4EMAPTPPARG
SCHEMBL3783598 0.79 TSHR (0.36) EGLN1KDM4EMAPTENPP3ALPL
SCHEMBL3771013 0.78 EGLN1 (0.39) EGLN1PTGDR2KDM4ELMNAALDH1A1
SCHEMBL27826429 0.78 KDM4E (0.38) EGLN1KDM4EMAPTENPP3ALPL
SCHEMBL3788385 0.78 PTGDR2 (0.43) PTGDR2MAPT
SCHEMBL3777897 0.76 PTGS2 (0.43) PTGDR2KDM4EMAPTLMNAALDH1A1
SCHEMBL3771036 0.74 LMNA (0.38) EGLN1THRBPTGDR2LMNAALDH1A1
SCHEMBL3781729 0.69 ALDH1A1 (0.41) KDM4ELMNAALDH1A1SMN1; SMN2
SCHEMBL15809203 0.68 CHRM1 (0.48) THRATHRBPTGDR2PPARGCHRM1
SCHEMBL3777522 0.68 PTGDR2 (0.45) PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
CN-101316591-B Quinoline compound and pharmaceutical application thereof ARGENTA ORAL THERAPEUTICS LTD. (GB) 2012-02-01 CN disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 EGLN1 3003/4885THRA 412/4885THRB 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.